Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK4 | O96013 | 1/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.31 |
| ▸ | ATR | Q13535 | 1/20 | 0.30 |
| ▸ | STAT3 | P40763 | 1/20 | 0.30 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17844714 | 0.93 | GABRA5 (0.38) | PAK4GABRA5PTK2ATRSTAT3 | |
| SCHEMBL18317475 | 0.82 | PAK4 (0.36) | PAK4GABRA5PTK2ATRSTAT3 | |
| SCHEMBL19742294 | 0.82 | PAK4 (0.37) | PAK4GABRA5PTK2STAT3RORC | |
| SCHEMBL17844731 | 0.81 | PAK4 (0.34) | PAK4STAT3 | |
| SCHEMBL19742272 | 0.79 | GABRA5 (0.37) | PAK4GABRA5PTK2ATRSTAT3 | |
| SCHEMBL17859423 | 0.79 | GABRA5 (0.41) | PAK4GABRA5STAT3RORC | |
| SCHEMBL17859431 | 0.79 | NTRK1 (0.37) | PAK4GABRA5RORC | |
| SCHEMBL17859425 | 0.77 | PAK4 (0.41) | PAK4GABRA5STAT3 | |
| SCHEMBL17859426 | 0.75 | PAK4 (0.41) | PAK4GABRA5STAT3 | |
| SCHEMBL17859536 | 0.75 | PAK4 (0.42) | PAK4GABRA5STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170369470-A1 | Cyclic Compounds and Uses Thereof | Karyopharm Therapeutics Inc. | 2017-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170369470-A1 | Cyclic Compounds and Uses Thereof | MALT1, BCL9, BCL6 | PAK4 1077/4885GABRA5 2240/4885PTK2 3820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.